Cancer Archives

News and Trends 20 Oct 2014

European’s First Personalized Vaccines to Treat Brain Cancer

A novel concept of fully personalized therapeutic cancer vaccines, called Glioma Actively Personalized VAccine Consortium (GAPVAC), has been moved into the clinic. It is the first european approval for such a technology. The project is lead by two german Biotech companies Immatics biotechnologies and BioNTech, and received a €6 million grant from European Union. The German National Authorities has approved the […]

October 20, 2014 - 3 minutesmins - By Julie Lellouche

News and Trends 16 Oct 2014

A Smart Collaboration to Diagnostic and Fight Cancer

New Oncology announced that it has entered into a collaboration agreement with Gustave Roussy Cancer Campus, Paris. Under this agreement, New Oncology (Cologne-based German Biotech company) will perform comprehensive parallel multigene testing to identify therapeutically relevant alterations in cancer-related genes. New Oncology will apply its proprietary diagnostic platform ‘NEO’, which allows rapid sample processing compatible with both […]

October 16, 2014 - 3 minutesmins - By Julie Lellouche

News and Trends 15 Oct 2014

New Peptide Technology Against Cancer bags 25 Million Euros

Bicycle Therapeutics, a next generation biotherapeutics UK-based company developing first-in-class bicyclic peptides, announced that it had secured an equity financing of €25 million for the clinical development of therapeutic bicycle drug candidates in oncology. Bicycle has used its proprietary bicyclic peptide technology that enables to discover a new class of drug candidates, which have similar selectivity […]

October 15, 2014 - 3 minutesmins - By Julie Lellouche

News and Trends 15 Oct 2014

Recently Launched Company Rigontec already Raised 9,45M Euros against Cancer

Rigontec GmbH, a German privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, announced the first closing of its Series A financing round, raising €9.45 million. Rigontec was launched in January 2014 as a spin-out of the Institute for Clinical Chemistry and Clinical Pharmacology at the University of Bonn, Germany. The Company’s […]

October 15, 2014 - 2 minutesmins - By Julie Lellouche

csm ganymed start bilder04 new 7ec1db04d4

News and Trends 2 Oct 2014

BioNTech and Ganymed Pharmaceuticals Open One of the Largest Research Facilities in Germany

BioNTech AG and Ganymed Pharmaceuticals AG, two leading German biotechnology companies, announced today the joint- opening of a new headquarters and research facility of approximatively 10,000 square-meters. The new facility brings together 300 employees and is located close to academic institutions (Johannes-Gutenberg University), hospitals (University Medical Center) and cancer research institutions such as the leading translational oncology […]

October 2, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 30 Sep 2014

New Collaboration for New Cancer Therapies

Medimmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca, has entered into a collaboration to establish a joint lab in Cambridge, UK, with Cancer Research Technology, the commercial arm of Cancer Research UK. The new laboratory will be the first partnership of its kind of both organizations, and will focus on […]

September 30, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 26 Sep 2014

An Innovative Test to Detect Colon Cancer on Time

The AIT Austrian Institute of Technology, BioVendor and SCIENION today announced that the three organizations will partner on the development of an in-vitro diagnostic test for colon cancer. The innovative test kit shall identify cancer at an early stage based on tumor autoantibody biomarkers. The three structures will work closely together to develop the in-vitro diagnostic test […]

September 26, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 25 Sep 2014

A New Financial Hope for Start-ups Focused on Cancer

Aglaia is a new venture capital fund that will invest in about ten to fifteen biotechnology start-ups developing groundbreaking technologies to prevent and cure cancer. The Dutch venture has announced the launch of Aglaia Oncology Fund II. Investors contribute with $65M (EUR 51M) for the fund, to reach $80M (EUR 63M) to $100M (EUR 80M). Like […]

September 25, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 22 Sep 2014

Is a new revolution in lung cancer drug treatment coming ?

A new revolutionary treatment could help cure lung cancer. It is based on mRNA instead of antibodies and chemotherapy. Instead of delivering the protein or the drug, only a message is delivering and the body will produce the therapeutics. Curevac, the historic and one of the leading Biotech company in this field announced a 465 million […]

September 22, 2014 - 3 minutesmins - By Philip Hemme

News and Trends 1 Sep 2014

Fighting prostate cancer with a tomato-rich diet

Men who eat over 10 portions a week of tomatoes have an 18 per cent lower risk of developing prostate cancer, new research suggests. With 35,000 new cases every year in the UK, and around 10,000 deaths, prostate cancer is the second most common cancer in men worldwide. Rates are higher in developed countries, which […]

September 1, 2014 - 3 minutesmins - By Julie Lellouche

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us